Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead.

Sprouting angiogenesis is an invasive process that involves proteolytic activities required for the degradation of the endothelial basement membrane, cell migration with removal of obstructing matrix proteins, and generation of space in the matrix to allow endothelial cells to form a proper lumen. In the last decade it has become clear that besides these matrix-degrading properties, proteases exert additional, more subtle functions that play a key role in angiogenesis. These functions are discussed with specific emphasis on membrane type-1 matrix metalloproteinase (MT1-MMP), other MMPs, and the related ADAMs (a disintegrin and metalloproteinase domain). Proteases modulate the balance between pro- and anti-angiogenic factors by activation and modification of growth factors and chemokines, ectodomain shedding with accompanied receptor activation, shedding of cytokines from membrane-bound precursors, and generation of (matrix) protein fragments that inhibit or activate angiogenesis. Furthermore, they participate in the recruitment of leukocytes and progenitor cells, which contribute to the onset and progression of angiogenesis. Proteases facilitate the mobilization of progenitor cells in the bone marrow as well as the entry of these cells and leukocytes into the angiogenic area. The interaction between pericytes and the newly formed endothelial tubes is accompanied by silencing of MMP activities. Better understanding of the various activities of proteases may be helpful in developing more specific inhibitors that could result in tailor-made modification of proteolytic activities in disease.

[1]  G. Rossi,et al.  Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. , 2005, Blood.

[2]  S. Apte,et al.  Egr-1 Mediates Extracellular Matrix-driven Transcription of Membrane Type 1 Matrix Metalloproteinase in Endothelium* , 1999, The Journal of Biological Chemistry.

[3]  M. Hollenberg,et al.  Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. , 2001, The Biochemical journal.

[4]  Stephen J. Weiss,et al.  Regulation of Cell Invasion and Morphogenesis in a Three-Dimensional Type I Collagen Matrix by Membrane-Type Matrix Metalloproteinases 1, 2, and 3 , 2000, The Journal of cell biology.

[5]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[6]  Kenji Nakamura,et al.  Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells , 2007, Journal of Cell Science.

[7]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[8]  Christopher M Overall,et al.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.

[9]  J. Gutkind,et al.  MT1-MMP Controls Tumor-induced Angiogenesis through the Release of Semaphorin 4D* , 2007, Journal of Biological Chemistry.

[10]  Bonnie F. Sloane,et al.  Pericellular cathepsin B and malignant progression , 2003, Cancer and Metastasis Reviews.

[11]  G. Davis,et al.  Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3 , 2006, The Journal of cell biology.

[12]  B. Sumpio,et al.  Transcription Factor Sp1 Phosphorylation Induced by Shear Stress Inhibits Membrane Type 1-Matrix Metalloproteinase Expression in Endothelium* , 2002, The Journal of Biological Chemistry.

[13]  D. Gingras,et al.  Src-dependent Phosphorylation of Membrane Type I Matrix Metalloproteinase on Cytoplasmic Tyrosine 573 , 2007, Journal of Biological Chemistry.

[14]  D. Rifkin,et al.  Proteolytic control of growth factor availability , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[15]  J. Joyce,et al.  Cysteine Cathepsins and the Cutting Edge of Cancer Invasion , 2007, Cell cycle.

[16]  P. Carmeliet Angiogenesis in health and disease , 2003, Nature Medicine.

[17]  P. Quax,et al.  Pericellular proteases in angiogenesis and vasculogenesis. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[18]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[19]  T. Ohtsuka,et al.  RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity , 2007, Nature Neuroscience.

[20]  D. Edwards,et al.  Metalloproteinases and their inhibitors in tumor angiogenesis , 2005, International journal of cancer.

[21]  M. Yáñez-Mó,et al.  Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. , 2005, Blood.

[22]  R. Maehr,et al.  Invariant Chain Controls the Activity of Extracellular Cathepsin L , 2002, The Journal of experimental medicine.

[23]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[24]  J. Foidart,et al.  Expression Pattern of Metalloproteinases and Tissue Inhibitors of Matrix-Metalloproteinases in Cycling Human Endometrium1 , 2003, Biology of reproduction.

[25]  R. Raedt,et al.  Endothelial Outgrowth Cells Are Not Derived From CD133+ Cells or CD45+ Hematopoietic Precursors , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[26]  小崎 直人 Impaired bone fracture healing in matrix metalloproteinase-13 deficient mice , 2007 .

[27]  Michael P Vitek,et al.  Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways , 2007, Proceedings of the National Academy of Sciences.

[28]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[29]  J. Keiser,et al.  Hepatocyte growth factor enhances MMP activity in human endothelial cells. , 2000, Biochemical and biophysical research communications.

[30]  G. Murphy,et al.  Identification of the Extracellular Matrix (ECM) Binding Motifs of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Effective Transfer to TIMP-1* , 2007, Journal of Biological Chemistry.

[31]  V. V. van Hinsbergh,et al.  Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. , 2001, Blood.

[32]  E. Chavakis,et al.  Cathepsin L is required for endothelial progenitor cell–induced neovascularization , 2005, Nature Medicine.

[33]  S. Itohara,et al.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.

[34]  Motoharu Seiki,et al.  Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. , 2003, Cancer letters.

[35]  J. Liao,et al.  Serveur Académique Lausannois SERVAL serval.unil.ch , 2022 .

[36]  Andrew J. Ewald,et al.  Matrix metalloproteinases and the regulation of tissue remodelling , 2007, Nature Reviews Molecular Cell Biology.

[37]  Noriko Ito,et al.  Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. , 2006, Molecular biology of the cell.

[38]  James P. Quigley,et al.  Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer , 2003, Cancer and Metastasis Reviews.

[39]  Chiaki Takahashi,et al.  RECK: A novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling , 2003, Cancer and Metastasis Reviews.

[40]  Yasufumi Sato Role of aminopeptidase in angiogenesis. , 2004, Biological & pharmaceutical bulletin.

[41]  M. Luisa Iruela-Arispe,et al.  Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors , 2005, The Journal of cell biology.

[42]  W. Stetler-Stevenson,et al.  Shp-1 Mediates the Antiproliferative Activity of Tissue Inhibitor of Metalloproteinase-2 in Human Microvascular Endothelial Cells* , 2006, Journal of Biological Chemistry.

[43]  P. Polverini Role of the macrophage in angiogenesis-dependent diseases. , 1997, EXS.

[44]  D. Gingras,et al.  Activation of the extracellular signal‐regulated protein kinase (ERK) cascade by membrane‐type‐1 matrix metalloproteinase (MT1‐MMP) , 2001, FEBS letters.

[45]  T. Gridley Notch signaling in vascular development and physiology , 2007, Development.

[46]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[47]  F. Dignat-George,et al.  High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors , 2006, Thrombosis and Haemostasis.

[48]  M. Ratajczak,et al.  Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. , 2000, Experimental hematology.

[49]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[50]  A. Strongin,et al.  Centrosomal Pericentrin Is a Direct Cleavage Target of Membrane Type-1 Matrix Metalloproteinase in Humans but Not in Mice , 2005, Journal of Biological Chemistry.

[51]  Fuquan Yang,et al.  Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. , 2005, Blood.

[52]  G. Zheng,et al.  Production of matrix metalloproteinase-9 by cord blood CD34+ cells and its role in migration , 2004, Annals of Hematology.

[53]  Hiroshi Ohno,et al.  Cytoplasmic tail–dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity , 2001, The Journal of cell biology.

[54]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[55]  R. W. Rauser,et al.  Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Motoharu Seiki,et al.  MT1‐MMP: A potent modifier of pericellular microenvironment , 2006, Journal of cellular physiology.

[57]  G. Rossi,et al.  In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer. , 2006, Cancer research.

[58]  Xu-wen Liu,et al.  Novel functions of TIMPs in cell signaling , 2006, Cancer and Metastasis Reviews.

[59]  S. Dimmeler,et al.  Endothelial Progenitor Cells: Characterization and Role in Vascular Biology , 2004, Circulation research.

[60]  L. Claesson‐Welsh,et al.  A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 , 2003, Nature Medicine.

[61]  M. Reed,et al.  Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? , 2003, Journal of the National Cancer Institute.

[62]  C. Overall,et al.  TIMP Independence of Matrix Metalloproteinase (MMP)-2 Activation by Membrane Type 2 (MT2)-MMP Is Determined by Contributions of Both the MT2-MMP Catalytic and Hemopexin C Domains* , 2006, Journal of Biological Chemistry.

[63]  P. ten Dijke,et al.  Extracellular control of TGFbeta signalling in vascular development and disease. , 2007, Nature reviews. Molecular cell biology.

[64]  Neil D. Rawlings,et al.  Handbook of proteolytic enzymes , 1998 .

[65]  Hyun-Jai Cho,et al.  Cytokines and Matrix Metalloproteinases Progenitor Cells and Late Outgrowth Endothelial Cells: the Role of Angiogenic Synergistic Neovascularization by Mixed Transplantation of Early Endothelial Synergistic Neovascularization by Mixed Transplantation of Early Endothelial Progenitor Cells and Late Ou , 2022 .

[66]  P. Dijke,et al.  Extracellular control of TGFβ signalling in vascular development and disease , 2007, Nature Reviews Molecular Cell Biology.

[67]  S. Rafii,et al.  Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9–mediated progenitor cell mobilization , 2005, The Journal of experimental medicine.

[68]  C. Overall,et al.  Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1* , 2001, The Journal of Biological Chemistry.

[69]  M. Iruela-Arispe,et al.  ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2 , 2006, The EMBO journal.

[70]  Ji Ming Wang,et al.  The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[71]  P. Carmeliet,et al.  uPAR: a versatile signalling orchestrator , 2002, Nature Reviews Molecular Cell Biology.

[72]  R. Kalluri Basement membranes: structure, assembly and role in tumour angiogenesis , 2003, Nature reviews. Cancer.

[73]  S. Groshen,et al.  Stromal Matrix Metalloproteinase-9 Regulates the Vascular Architecture in Neuroblastoma by Promoting Pericyte Recruitment , 2004, Cancer Research.

[74]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[75]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[76]  C. Heeschen,et al.  Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.

[77]  Jeffrey W. Smith,et al.  Proteolysis of the Membrane Type-1 Matrix Metalloproteinase Prodomain , 2007, Journal of Biological Chemistry.

[78]  Pieter Koolwijk,et al.  Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. , 2004, The Journal of clinical endocrinology and metabolism.

[79]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[80]  B. Levkau,et al.  ADAM15 is an adherens junction molecule whose surface expression can be driven by VE-cadherin. , 2002, Experimental cell research.

[81]  T. Asahara,et al.  Endothelial progenitor cells for postnatal vasculogenesis. , 2004, American journal of physiology. Cell physiology.

[82]  G. Nickenig,et al.  Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[83]  B. Bauvois Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? , 2004, Oncogene.

[84]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[85]  M. Stack,et al.  Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion , 2007, Nature Cell Biology.

[86]  Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration , 2003 .

[87]  K. Gray,et al.  Roles and regulation of membrane-associated serine proteases. , 2007, Biochemical Society transactions.

[88]  D. Seals,et al.  The ADAMs family of metalloproteases: multidomain proteins with multiple functions. , 2003, Genes & development.

[89]  Stefan Rose-John,et al.  Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)* , 2003, Journal of Biological Chemistry.

[90]  H. Mori,et al.  CD44 directs membrane‐type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin‐like domain , 2002, The EMBO journal.

[91]  V. V. van Hinsbergh,et al.  Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. , 1993, The Biochemical journal.

[92]  R. Khokha,et al.  TIMP-3 Deficiency Leads to Dilated Cardiomyopathy , 2004, Circulation.

[93]  Pawan Kumar,et al.  Src and phosphatidylinositol 3-kinase mediate soluble E-selectin-induced angiogenesis. , 2003, Blood.

[94]  U. Weidle,et al.  Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. , 1999, The American journal of pathology.

[95]  R. Williamson,et al.  Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. , 2003, Biochemical Society symposium.

[96]  R. Hynes,et al.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.

[97]  María Yáñez-Mó,et al.  Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. , 2003, Molecular biology of the cell.

[98]  M. Yoder,et al.  Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. , 2007, Experimental hematology.

[99]  F. Blasi,et al.  Metalloproteases Cleave the Urokinase-Type Plasminogen Activator Receptor in the D1-D2 Linker Region and Expose Epitopes not Present in the intact Soluble Receptor , 2002, Thrombosis and Haemostasis.

[100]  M. Iruela-Arispe,et al.  Thrombospondin modules and angiogenesis. , 2004, The international journal of biochemistry & cell biology.

[101]  A Cumano,et al.  A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. , 2000, Molecular cell.

[102]  K. Horiuchi,et al.  Potential Role for ADAM15 in Pathological Neovascularization in Mice , 2003, Molecular and Cellular Biology.

[103]  U. Sen,et al.  Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1)* , 2006, Journal of Biological Chemistry.

[104]  J. Foidart,et al.  Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. , 2006, Cancer research.

[105]  Antonio S. Tutor,et al.  Functional interplay between endothelial nitric oxide synthase and membrane type 1 matrix metalloproteinase in migrating endothelial cells. , 2007, Blood.

[106]  Ronit Vogt Sionov,et al.  CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.

[107]  G. Weskamp,et al.  Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands , 2004, The Journal of cell biology.

[108]  J. Couchman,et al.  Palmitoylation at Cys574 is essential for MT1‐MMP to promote cell migration , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  C. Blobel,et al.  Adam Meets Eph: An ADAM Substrate Recognition Module Acts as a Molecular Switch for Ephrin Cleavage In trans , 2005, Cell.

[110]  R. Hynes,et al.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.

[111]  A. Newby,et al.  Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. , 2005, Physiological reviews.

[112]  B. de Strooper,et al.  The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. , 2002, Human molecular genetics.

[113]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[114]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[115]  Lance C Bridges,et al.  ADAM-Integrin Interactions: potential integrin regulated ectodomain shedding activity. , 2005, Current pharmaceutical design.

[116]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[117]  S. Salzano,et al.  The Cleavage of the Urokinase Receptor Regulates Its Multiple Functions* , 2002, The Journal of Biological Chemistry.

[118]  Takanori Aoki,et al.  Matrix Metalloproteinases Cleave Connective Tissue Growth Factor and Reactivate Angiogenic Activity of Vascular Endothelial Growth Factor 165* , 2002, The Journal of Biological Chemistry.

[119]  D. Edwards,et al.  The ADAMTS metalloproteinases. , 2005, The Biochemical journal.

[120]  T. Tahir,et al.  Regulated Proteolytic Processing of Tie1 Modulates Ligand Responsiveness of the Receptor-tyrosine Kinase Tie2* , 2007, Journal of Biological Chemistry.

[121]  J. Foidart,et al.  Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. , 2008, Biochimie.

[122]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[123]  G. Murphy,et al.  Delineating the Molecular Basis of the Inactivity of Tissue Inhibitor of Metalloproteinase-2 against Tumor Necrosis Factor-α-converting Enzyme* , 2004, Journal of Biological Chemistry.

[124]  R. Sidman,et al.  Impaired angiogenesis in aminopeptidase N-null mice , 2007, Proceedings of the National Academy of Sciences.

[125]  Stephen J. Weiss,et al.  MT1-MMP–dependent neovessel formation within the confines of the three-dimensional extracellular matrix , 2004, The Journal of cell biology.

[126]  David A. Davis,et al.  Differential processing of stromal-derived factor-1α and stromal-derived factor-1β explains functional diversity , 2004 .